戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 notype and freedom from first grade > or =3A rejection episode.
2 t accepted the allograft permanently after a rejection episode.
3 redict functional outcome following an acute rejection episode.
4 months, four patients have not experienced a rejection episode.
5 ment with pulse steroid therapy to treat the rejection episode.
6  418 serum samples, including 35 paired to a rejection episode.
7              Among 98 subjects, 37% had >/=1 rejection episode.
8 and grafts after successful treatment of the rejection episode.
9 ents were symptomatic and 7 did not note the rejection episode.
10 c tacrolimus concentrations may induce acute rejection episodes.
11 nd in the early post-ITx period during first rejection episodes.
12 mild (n=4), moderate (n=2), and severe (n=1) rejection episodes.
13 d continuous vigilance is required to detect rejection episodes.
14 of bowel on initial endoscopy, and number of rejection episodes.
15 ay in fact be missed concordant kidney acute rejection episodes.
16 ab and three Thymoglobulin patients suffered rejection episodes.
17 al function was attained in patients without rejection episodes.
18                          There were no acute rejection episodes.
19 y initial immunosuppression to prevent early rejection episodes.
20 jection and would resolve after treatment of rejection episodes.
21 recipients at increased risk for early acute rejection episodes.
22 y of renal function with a low risk of acute rejection episodes.
23 ) survival, complications, and biopsy-proven rejection episodes.
24 ymocyte Globulin) was used to treat putative rejection episodes.
25 n episodes, and seven experienced mild acute rejection episodes.
26 and were evaluated retrospectively regarding rejection episodes.
27 s or the incidence of biopsy-confirmed acute-rejection episodes.
28 d after immunosuppressive therapy in 9 of 11 rejection episodes.
29 .2%) patients developed a total of six acute rejection episodes.
30 he absence of rejection would predict future rejection episodes.
31 gnificant increase in the incidence of acute rejection episodes.
32 ts on subsequent graft survival or number of rejection episodes.
33 oup of children with no early clinical acute rejection episodes.
34 ifically home to the graft epithelium during rejection episodes.
35 y predict the subsequent occurrence of acute rejection episodes.
36 p, current pharmacological regimen, and late rejection episodes.
37 erved between patients with or without early rejection episodes.
38 correlated positively with mild and moderate rejection episodes.
39 E patients who experienced greater than four rejection episodes.
40  grafts, but not in recipients with multiple rejection episodes.
41 equent (P=0.034) and earlier (P=0.065) acute rejection episodes.
42 resulted in a significant reduction in acute rejection episodes.
43 time points compared with eyes without graft rejection episodes.
44  biopsy, caused by hepatitis C recurrence or rejection episodes.
45 -DSA showed the highest likelihood to suffer rejection episodes.
46 3 years (mean, 28 months) without subsequent rejection episodes.
47 o differences in incidences of biopsy-proven rejection episodes.
48 drawn due to return of underlying disease or rejection episodes.
49 or glaucoma surgery (P < 0.0001) and a prior rejection episode (0.0023) were the significant risk fac
50 ed viruria was associated with more putative rejection episodes (0.62 vs. 0.33 per patient, P=0.006)
51 to determine the cumulative probability of a rejection episode 1 and 2 years after surgery.
52 . 0.9 mg/dL; P<0.001) and in all grafts with rejection episodes (1.2 vs. 0.9 mg/dL; P<0.05).
53 on, p < 0.05) and hemodynamically comprising rejection episodes (1.3 +/- 1.9 vs. 0.7 +/- 1.3, overall
54 /- 7%), despite an increased number of early rejection episodes (1.7 +/- 1.6 vs. 0.7 +/- 1.3, overall
55 . 25%, P=0.04), more likely to have a second rejection episode (13% vs. 4%; P=0.03), or to have recei
56 ke (3.30 [1.31-8.28]), and one or more acute rejection episode (13.89 [4.78-40.37]).
57        Twenty-seven recipients experienced a rejection episode, 14 of which had CMV disease, mostly a
58 onders exhibited a higher incidence of acute rejection episodes (26%) than either basiliximab-treated
59 2 months, respectively (P<0.001); more acute rejection episodes 28.2% vs. 13.5% (P=0.012); and increa
60 total of 13 (31%) of 42 recipients developed rejection episodes 3 to 49 days after transplantation.
61 uency in the group of patients with multiple rejection episodes (35.1% and 18.4%) compared to rejecti
62 e significantly more likely to have an acute rejection episode (39% vs. 25%, P=0.04), more likely to
63 te), and all predisposed to subsequent acute rejection episodes (4/4), whereas there were no rejectio
64 r than 30 group were more likely to suffer a rejection episode (43% vs. 29%; P = 0.03).
65  that S patients had fewer post-30 day first rejection episodes (5.4%) when compared with the C group
66                    In transplants that had a rejection episode, 50% of PKs (17) and 60% of EKs (15) s
67                                Most putative rejection episodes (52.1%) occurred concurrently with vi
68                         Twenty-two out of 30 rejection episodes (73.3%) resolved with steroid treatme
69                    In transplants that had a rejection episode, 85% of PKs (41) and 76% of EKs (22) s
70 e the incidence and clinical course of graft rejection episodes after Descemet membrane endothelial k
71                                              Rejection episodes after parental liver transplantation
72  survival and reduced the incidence of acute rejection episodes after renal transplantation compared
73 ation, would predict the occurrence of acute rejection episodes after renal transplantation.
74 ients who may be at increased risk for acute rejection episodes after renal transplantation.
75                               Thirteen of 14 rejection episodes (all in the no steroid group) resolve
76                             The incidence of rejection episodes, allograft nephropathy, and graft los
77 duction of the incidence and the severity of rejection episodes, although we need to follow-up larger
78 id-resistant or Banff grades II or III acute rejection episodes among 14%, 55% (P=0.08), and 71% (P=0
79 ction in the incidence and severity of acute rejection episodes among patients maintained on tacrolim
80                           The mean number of rejection episodes among the three infants during the fi
81                                           In rejection episode analyses, multiple logistic regression
82 pretransplant regulation, seven had an acute rejection episode and four of these experienced graft lo
83  the level of Fas mRNA is reduced during the rejection episode and subsequently recovers.
84  of keratoplasty may be used to anticipate a rejection episode and/or to prevent an allograft rejecti
85 nd 4 mg/day resulted in lower rates of acute rejection episodes and efficacy failure than the 1 mg/da
86                                    Number of rejection episodes and hospital readmissions during the
87  be beneficial in reducing the occurrence of rejection episodes and improving graft survivals.
88 SRDS) data from 1987 to 1997 regarding acute rejection episodes and infectious deaths.
89                          Patients with graft rejection episodes and late endothelial failure were ide
90                          There were no acute rejection episodes and no opportunistic infections.
91  or third-party MSCs resulted in reversal of rejection episodes and prolongation of islet function in
92  variations in susceptibility to early graft rejection episodes and recurrence of hepatitis C infecti
93                      Cumulative incidence of rejection episodes and rejection irreversibility rate.
94 in outcome measures: Cumulative incidence of rejection episodes and rejection irreversibility rate.
95 ents had a greater frequency and severity of rejection episodes and required more immunosuppression.
96 us therapy benefited the resolution of acute rejection episodes and significantly reduced the risk of
97 cipients, i.e., patients with no prior acute rejection episodes and stable renal function ("stable" p
98  and the incidence and severity of the acute rejection episodes and to determine the safety and toler
99 id not develop rejection, 123 who showed one rejection episode, and 57 patients who suffered from mul
100 einuria, the occurrence of a post-PAK kidney rejection episode, and interval between kidney and pancr
101 to P interval of over 1 year, pre-PAK kidney rejection episode, and pre-PAK proteinuria.
102 dence of acute tubular necrosis (ATN), acute rejection episodes, and causes of graft failure in perit
103 ysis for more than 1 year, one or more acute rejection episodes, and donor age older than 55.
104  recipients is a major risk factor for graft rejection episodes, and it has significant financial imp
105 rophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression re
106 rum creatinine level, number and severity of rejection episodes, and patient and graft survival rates
107 neal vascularization, surgical complication, rejection episodes, and postoperative medication were co
108 cluding donor and recipient characteristics, rejection episodes, and serology were prospectively reco
109 severe rejection, three experienced moderate rejection episodes, and seven experienced mild acute rej
110 CV recurrence, the number and grade of acute rejection episodes, and the histological course of HCV r
111 that occurrence, timing, and number of acute rejection episodes are associated with increased risk of
112  of anti-HLA antibodies at the time that the rejection episodes are diagnosed.
113                                   Most acute-rejection episodes are mild and do not lead to clinicall
114 n the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control g
115 ties, on the incidence and severity of acute rejection episodes as well as its tolerability were eval
116                    We observed 10 women with rejection episodes associated to pregnancy; these were 8
117 = 4), post keratoplasty patients with active rejection episodes associated with vessels; and group 4
118 The Kaplan-Meier cumulative probability of a rejection episode at 1 and 2 years was 1% and 1%, respec
119     Kaplan-Meier cumulative probability of a rejection episode at 3, 6, 12, and 24 months was 0%, 0.4
120 tion in the incidence of biopsy-proven acute rejection episodes at 12 months posttransplant (43% vs.
121 therapy and who had not experienced an acute rejection episode before month 6, serum creatinine level
122  surgery (HR, 5.23 [95% CI, 1.47-7.33]), and rejection episodes before PK failure (HR, 3.28 [95% CI,
123 s was used to determine the relative risk of rejection episodes between the 3 groups.
124                           One year after the rejection episodes, BSCVA and CCT in these eyes remained
125 with less early CNI nephrotoxicity and fewer rejection episodes, but comparable chronic arteriolar to
126 sive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials
127 yzed for time to first repeat and late acute rejection episodes by race, age at transplantation, and
128                                 During acute rejection episodes, CD8(+) T cells can contribute to lun
129 the rejector group, 19 patients presented 26 rejection episodes: clinically suspected (n=19) and biop
130 , fewer endocrine disorders, and fewer acute rejection episodes comparing adjunctive MMF and Tacro vs
131 d the asymptomatic nature of most histologic rejection episodes, controversy exists regarding the nee
132                       Patients who underwent rejection episodes could be started on CNI.
133  vs. cadaveric), native liver disease, acute rejection episodes, cytomegalovirus (CMV) infection, and
134                    Statins may prevent fatal rejection episodes, decrease terminal cancer risk, and r
135  biopsy-proven (Banff 1993 criteria) ongoing rejection episodes despite prior treatment with pulse an
136                                      A graft rejection episode developed in 12 patients (estimated pr
137 ipient gender distribution, HLA studies, and rejection episodes did not correlate with AIH recurrence
138     It was interesting that there were seven rejection episodes documented by biopsy at the approxima
139                               In less severe rejection episodes, DR3 and SODD were more focally induc
140 oid, even a weak one, was protective against rejection episodes during the second year after DMEK, wh
141                           A meta-analysis of rejection episodes found no significant benefit on eithe
142 lem, eight terminated because of one or more rejection episodes, four terminated because of adverse e
143 fter transplantation and monitored for acute rejection episodes, graft function, and graft survival.
144 ailure, occurrence of biopsy-confirmed acute rejection episodes, graft loss, or death, and various se
145 ncidence and severity of biopsy-proven acute rejection episodes, graft survival, patient survival, in
146                            Eyes with a graft rejection episode had a higher median percentage decline
147 h recipients with a history of > or =1 acute rejection episode had a higher serum creatinine level vs
148 rformed at the end of therapy showed that no rejection episodes had occurred.
149 ial fraction (30%) of biopsy-confirmed acute rejection episodes have a component of AHR as judged by
150                                    Recurrent rejection episodes have been linked to the subsequent de
151                        Patients experiencing rejection episodes have greater fluctuations in calprote
152                                           No rejection episodes have occurred.
153  adjusting for DSA_MFI_max, C4d, or previous rejection episodes, however lost their independent relat
154 were found to be at increased risk for acute rejection episodes if the allograft was mismatched for t
155         Allograft impairment was caused by a rejection episode in 84% (32/38) of patients with anti-H
156 d the onset of the first biopsy-proven acute rejection episode in patients with DGF from 29+/-43 days
157       Only 1 patient (0.7%) had a documented rejection episode in the DMEK group compared with 54 (9%
158  P = 0.03) more likely to undergo a > or =3A rejection episode in the first 12 months.
159 between a transplant in the second eye and a rejection episode in the first eye (KC P = .19, FED P =
160             Cumulative incidence of an acute rejection episode in the first year after transplantatio
161 overall relative risk of having at least one rejection episode in those who received fish oil was 0.9
162                                There were 23 rejection episodes in 13 patients with seven graft losse
163                                 The clinical rejection episodes in allografts were significantly asso
164 ection episodes (4/4), whereas there were no rejection episodes in ASK transplants without ATN (0/32;
165  phase II assessment of prophylaxis of acute rejection episodes in deceased donor renal allografts.
166                     There were few new acute rejection episodes in either study between years 1 and 2
167                              Among the seven rejection episodes in group 1, six of seven occurred amo
168 roids has proven to be effective in reducing rejection episodes in high-risk organ and islet cell tra
169 TN) on graft survival and incidence of acute rejection episodes in infant and small child recipients
170 and long-term rates of repeat and late acute rejection episodes in pediatric heart transplant (PHTx)
171 sporine (CsA) reduces the incidence of acute rejection episodes in renal allograft recipients.
172 ttractive choice for the prevention of acute rejection episodes in renal transplant patients.
173 o significantly decrease the number of acute rejection episodes in renal transplant recipients during
174 eported and presumed isolated pancreas acute rejection episodes in simultaneous pancreas kidney patie
175 effective in reducing the incidence of acute rejection episodes in SPKT recipients.
176                                          All rejection episodes in the non-HLAabs group appeared arou
177 eatinine less than 300 mumol/L with no acute rejection episodes in the preceding 6 months were enroll
178 l rate at 3 years, or in time to first acute-rejection episodes in the three groups.
179                                There were no rejection episodes in this group, and none of them requi
180                   The number and severity of rejection episodes increased when the liver was not incl
181                       The incidence of graft-rejection episodes is lower after DSEK compared with sta
182 e analysis demonstrated more moderate-severe rejection episodes (ISHLT > or = IIIA) at 2 months (0.83
183  intestinal allograft, delay in treatment of rejection episodes may result in rejection of the intest
184 fter randomization 23 patients experienced a rejection episode: MMF/pred (27.0%), MMF/CsA (6.8%) and
185                  The patient has had neither rejection episodes nor clinical manifestations of graft-
186 d IL-10 genes were not associated with acute rejection episodes, nor was the IL-4 receptor alpha-chai
187                                     Although rejection episodes occasionally required restoration of
188 nsplant recipients and, in many cases, acute rejection episodes occur because of escape of donor-reac
189                                  Most of the rejection episode occurred approximately 1 or 6 months a
190 emonstrated late endothelial failure, and no rejection episodes occurred (0%).
191                                              Rejection episodes occurred between 0.8 and 34 months.
192 ; Tac/MMF, 2.2%; triple therapy, 2.2%); Most rejection episodes occurred during the first 6 months of
193                                              Rejection episodes occurred in 9 of 17 IVIG and 1 of 10
194                                  Three acute rejection episodes occurred in the intervention group.
195                          Biopsy-proven acute rejection episodes occurred in three patients (two in th
196                                              Rejection episodes occurred throughout the first year bu
197                                No hyperacute rejection episodes occurred.
198 eterioration of graft function resulted from rejection episodes occurring more than 2 years after tra
199            A tolerant patient had a moderate rejection episode of 5.3 years after immunosuppression w
200 ents with a positive virtual XMs showed more rejection episodes of any types when comparing with pati
201 ollow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ f
202                        For example, multiple rejection episodes of the skin have been noted in clinic
203 cal course was complicated by an early acute rejection episode on posttransplant day (PTD) 6, that wa
204                       The effect of an acute rejection episode on the risk of developing CAF seems to
205  the incidence of acute rejection, number of rejection episodes or 1-year allograft survival among Bw
206 to the regimen when patients developed acute rejection episodes or adverse effects to steroids or MMF
207  it did not further reduce the rate of acute rejection episodes or increase graft survival compared t
208  no significant difference in cold ischemia, rejection episodes, or patient or graft survival.
209  in initial function, endoscopic appearance, rejection episodes, or transplant pancreatitis.
210 etween particular cytokine profile and early rejection episodes, our data strongly suggest an associa
211 who were TRI negative to have had a previous rejection episode (P=0.02).
212 er incidence of subsequent antibody-mediated rejection episodes (P < 0.001), but reduced death-censor
213  experienced earlier and more frequent acute rejection episodes (P=0.025).
214       The G group had a trend toward earlier rejection episodes (P=0.07), a significantly higher seru
215                                Neither acute rejection episodes (P=0.34) nor OKT3 use (P=0.36) before
216 er rate and higher histologic grade of acute rejection episodes, particularly proximate to the onset
217 onrandomized cohorts were compared for acute rejection episodes, patient and graft survival rates, re
218                   In addition, the number of rejection episodes per patient as well as renal function
219                            Average number of rejection episodes per patient totalled 1.6+/-1.2.
220  approaches, based on; i) DSA levels and ii) rejection episode post transplant.
221 the graft tubular epithelium during clinical rejection episodes, predicting a causal role for CD103+C
222                                          Any rejection episode prior to PK failure was a significant
223 comitant with the bout of HUS, namely, acute rejection episodes prior to (n=2) or during (n=3), and 2
224                        Acute renal allograft rejection episodes refractory to antilymphocyte preparat
225 th the age or sex of the donor or recipient, rejection episodes, renal biopsy, or drug-induced nephro
226  emergency hospitalizations, renal biopsies, rejection episodes, renal function, and blood concentrat
227                                  The initial rejection episode responded to steroid treatment in 93.4
228                                          All rejection episodes responded to treatment with alemtuzum
229  four histologically diagnosed, severe acute rejection episodes resulted in graft failure before reso
230 tion, survival of patients and grafts, acute rejection episodes, serum creatinine values, adverse eve
231       Samples taken at the time of a corneal rejection episode showed Fas mRNA levels were significan
232  from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL
233 had a 15 times lesser risk of experiencing a rejection episode than DSEK eyes (95% confidence limit [
234 nce of late (>6 months posttransplant) acute rejection episodes than did the LURD recipients (8.6% vs
235 -G levels were higher in patients with acute rejection episodes than nonrejectors.
236 unction displayed a lower incidence of acute rejection episodes than those with later recovery of fun
237     The sixth allograft had an early, severe rejection episode that limited renal growth and attainme
238 lotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by i
239 lotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by i
240                                    Thus, the rejection episodes that occur in these patients are in r
241          Despite the high incidence of acute rejection episodes, they can be completely reversed when
242  cumulative probability of immunologic graft rejection episodes through 2 years after DMEK.
243                             Numbers of acute rejection episodes, transplantation for autoimmune disea
244 ere collected on patient and graft survival, rejection episodes, urinary tract infection (UTI) requir
245 re higher in patients who subsequently had a rejection episode versus those who had no rejection (22.
246        The 3-year predicted probability of a rejection episode was 9% with DSAEK versus 20% with PKP
247                     The rate of at least one rejection episode was also significantly higher in the S
248                                            A rejection episode was considered to have occurred based
249 However, the incidence of a first reversible rejection episode was significantly higher for simultane
250                             The incidence of rejection episodes was 15% in both groups.
251      The frequency of biopsy-confirmed acute rejection episodes was also lower (2 mg 16.9%, p=0.002;
252 , the incidence of moderate and severe acute rejection episodes was found to be significantly lower a
253                                The number of rejection episodes was highest in group 4 and lowest in
254 ariate analysis, the cumulative incidence of rejection episodes was influenced by recipient age (P =
255                        A higher incidence of rejection episodes was observed in young patients (<20 y
256                  The cumulative incidence of rejection episodes was significantly greater in the no s
257                             The incidence of rejection episodes was significantly higher in pretransp
258                       The incidence of acute rejection episodes was significantly lower among group 1
259          The incidence and severity of acute rejection episodes was similar between both groups (7.8%
260 roscopy images before, during, and after the rejection episode were analyzed and compared with a case
261                        Patients with a graft rejection episode were followed up for 1 additional year
262   No serious or severe adverse events and no rejection episode were reported.
263 ients (1995-2005), 108 patients with a first rejection episode were selected for study using strict i
264 rior glaucoma surgeries, and occurrence of a rejection episode were the significant risk factors for
265              At 6 months, the rates of acute rejection episodes were 38.1% in the ISIS 2302 group ver
266                           Graft survival and rejection episodes were analyzed in this group and compa
267 led that grades indicating more severe acute rejection episodes were associated with a greater probab
268                                   Nine of 13 rejection episodes were associated with noncompliance.
269                Four of the 14 moderate acute rejection episodes were associated with unfavorable clin
270                              The majority of rejection episodes were Banff grade I and IIA and were f
271                                          All rejection episodes were biopsy confirmed.
272 ring the first posttransplant year the acute rejection episodes were characterized by reversible oede
273 imited to azathioprine and prednisone, acute rejection episodes were common, and it was difficult to
274           Among the 3268 biopsies, 180 acute rejection episodes were diagnosed (88 indeterminate, 74
275                                    All acute rejection episodes were documented by biopsy and were cl
276                                           No rejection episodes were documented during the PVAN treat
277                                              Rejection episodes were evaluated after exclusion of pat
278 ent survivals, reason for graft failure, and rejection episodes were evaluated in 221 intestinal reci
279                      A total of 299 cases of rejection episodes were identified, of which 145 (48.5%)
280                    In nontolerant recipients rejection episodes were mild and resolved over 5.6 month
281                                              Rejection episodes were more likely to be irreversible f
282 rast, the 74 mild and 88 indeterminate acute rejection episodes were not associated with unfavorable
283                                              Rejection episodes were not observed in the three macroc
284                                     However, rejection episodes were not significantly different amon
285 rrelated well with HA titers and importantly rejection episodes were preempted by a rising relative m
286                                              Rejection episodes were restricted to the pediatric CAD
287                                        Graft rejection episodes were seen in 5 eyes (12.1%) in the PK
288                                              Rejection episodes were seen in a greater proportion of
289 nd year after DMEK, whereas 6% experienced a rejection episode when steroids were discontinued.
290           One patient experienced a clinical rejection episode, which was successfully treated.
291 red off steroids were treated for subsequent rejection episodes, which were all steroid sensitive, an
292 nts experiencing a first biopsy-proven acute rejection episode while receiving CsA-ME were randomized
293 he lowest MR2* levels were observed in acute rejection episodes with vascular injury i.e. IIA and C4d
294 es with no rejection and the occurrence of a rejection episode within 2 months.
295 significantly reduced risk of experiencing a rejection episode within 2 years after surgery compared
296  highly predictive of clinically significant rejection episodes within 1 year of orthotopic heart tra
297 ad multiple biopsy proven or severe clinical rejection episodes within the first 21 days and only one
298 %, or 25.7% incidence of biopsy-proven acute rejection episodes within the first 6 months posttranspl
299            All patients developed reversible rejection episodes within the first month that were char
300 eripheral blood leukocyte genes that trigger rejection episodes would be evident late after ITx durin

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top